Opus Genetics is trading 5.7% down at $5.49 on September 16, 2026, as biotech sentiment weakens in the absence of a new company-specific announcement.
- The decline appears primarily sector-driven, while broader indexes hold gains; confidence is medium.
- The latest identifiable catalyst was positive OPGx-BEST1 clinical data and FDA Type C meeting progress announced September 9, which had previously lifted shares.